Treatment for Autosomal Dominant Hypocalcemia in Proof of Concept Study
Following the recent announcement of Shire buying NPS Pharma for $5.2 Billion, many are interested in the pipeline Shire will be acquiring. In this exclusive interview with Francois Nader, MD, MBA, president, chief executive officer, and director of NPS Pharmaceuticals, Dr Nader discusses the company’s orphan drug in development - NPSP795 – which is currently in a phase 2a proof of concept study to treat autosomal dominant hypocalcemia.
Autosomal dominant hypocalcemia is an ultra rare condition in which patients lack a functioning calcium sensing receptor in the parathyroid gland.
For more information about the company and autosomal dominant hypocalcemia, visit www.npsp.com